Home › All Companies › BCDA

BioCardia, Inc. (BCDA)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-05-08

Key Insights

  • FDA confirmed two viable regulatory pathways for Helix Transendocardial Delivery Catheter System approval, with no safety or performance concerns raised, reducing development risk for the company's key device.
  • FDA's preferred approval route is simultaneous clearance of Helix with CardiAMP cell therapy for heart failure treatment, suggesting regulatory alignment and potential for combined market entry that could accelerate commercialization.
  • Alternative DeNovo pathway approval option provides strategic flexibility if the simultaneous approval strategy faces delays, giving BioCardia multiple routes to market for its lead product.
Sentiment: Positive Significance: 7/10
View Original Filing →
Current Report Filed: 2026-04-28

Key Insights

  • BioCardia received allowance of a Japanese patent for Heart3D™ Fusion Imaging technology, strengthening intellectual property protection for their proprietary image-guided navigation software used in CardiAMP Cell Therapy procedures.
  • The patent covers 'Target Site Selection, Entry, and Update with Automatic Remote Image Annotation,' indicating innovation in real-time surgical guidance capabilities that could enhance competitive positioning in interventional cardiology.
  • This international patent protection expansion suggests BioCardia is pursuing global market opportunities and building a defensible moat around their core Heart3D technology platform.
Sentiment: Positive Significance: 5/10
View Original Filing →
Insider Trading Filed: 2026-04-22

Key Insights

  • CEO Peter Altman acquired 1,000 shares of BCDA stock across two trading days (April 20-21, 2026) at approximately $1.23 per share, totaling roughly $1,230 in purchases, suggesting confidence in the company's near-term direction.
  • The transactions were executed through multiple trades at slightly varying prices ($1.21-$1.27 range), indicating active market participation rather than a single block purchase, typical of deliberate accumulation strategies.
  • Altman's beneficial ownership increased from approximately 274,766 to 275,766 shares following these purchases, demonstrating incremental but consistent insider investment in the company.
Sentiment: Neutral Significance: 3/10
View Original Filing →
Current Report Filed: 2026-04-15

Key Insights

  • BioCardia, Inc. has failed to meet the minimum stockholders' equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market, and the company has until May 25, 2026 to submit a plan to regain compliance.
  • The company's inability to meet the listing requirement may indicate financial difficulties or challenges in the business that could impact its long-term viability.
  • Investors should closely monitor the company's progress in submitting a plan and regaining compliance, as a potential delisting from Nasdaq could significantly affect the stock's trading and liquidity.
Sentiment: Negative Significance: 7/10
View Original Filing →
Current Report Filed: 2026-04-02

Key Insights

  • BioCardia has submitted the CardiAMP HF clinical study data to the FDA, indicating potential progress in the development of their lead product candidate.
  • The company plans to meet with the FDA to discuss the accelerated approval pathway for the CardiAMP System for ischemic chronic heart failure with reduced ejection fraction (HFrEF), which could expedite the approval process.
  • The company's ability to navigate the regulatory landscape and potentially obtain accelerated approval for the CardiAMP System could be a significant milestone for the company and its investors.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-03-26

Key Insights

  • The reporting person, Peter Altman, who is the President and CEO of BioCardia, Inc. (BCDA), has purchased 600 shares of the company's common stock on March 24, 2026 at a weighted average price of $1.24 per share, and an additional 300 shares on March 25, 2026 at a weighted average price of $1.22 per share.
  • The insider buying activity suggests that the CEO has confidence in the company's prospects and is willing to invest their own capital in the stock.
  • The relatively small size of the transactions, totaling 900 shares, indicates that the insider's buying is likely for personal investment purposes rather than a significant strategic move.
Sentiment: Positive Significance: 5/10
View Original Filing →
Annual Report Filed: 2026-03-24

Key Insights

  • The company completed several financing rounds in 2024 and 2025, including ATM offerings, warrant issuances, and common stock sales, which provided additional capital to support its operations.
  • BioCardia reported increases in research and development expenses as well as selling, general, and administrative expenses in 2024 and 2025, indicating ongoing investment in its product development and commercialization efforts.
  • The company disclosed customer concentration risk, with a significant portion of its revenue coming from a small number of customers, which could expose it to potential volatility.
Sentiment: Neutral Significance: 6/10
View Original Filing →
Current Report Filed: 2026-03-24

Key Insights

  • BioCardia, Inc. announced its financial results for the year ended December 31, 2025, providing investors with an update on the company's performance and operations.
  • The 8-K filing does not indicate any material agreements, leadership changes, or other significant corporate events beyond the financial results disclosure.
  • Without additional context on the company's financials, product pipeline, or strategic initiatives, the significance of this filing is limited.
Sentiment: Neutral Significance: 3/10
View Original Filing →
Current Report Filed: 2026-03-17

Key Insights

  • BioCardia, Inc. has received FDA acceptance of its pre-submission package for the Helix Transendocardial Delivery Catheter, indicating progress in the regulatory approval process for this key product.
  • The Helix catheter is intended for intramyocardial therapeutic and diagnostic agent delivery, which could expand BioCardia's product portfolio and addressable market.
  • Receiving FDA acceptance of the pre-submission package is an important milestone that suggests BioCardia is advancing its regulatory strategy for the Helix catheter.
Sentiment: Positive Significance: 7/10
View Original Filing →
Current Report Filed: 2026-03-03

Key Insights

  • BioCardia reported positive late-breaking echocardiography results from its Phase III clinical trial for ischemic heart failure, suggesting potential efficacy of their therapy.
  • The results were presented by a respected professor and co-principal investigator of the trial, lending credibility to the findings.
  • The favorable data, if confirmed, could significantly advance BioCardia's pipeline and increase investor confidence in the company's prospects.
Sentiment: Positive Significance: 7/10
View Original Filing →
Current Report Filed: 2026-02-10

Key Insights

  • BioCardia has completed a Pre-Submission under the Q-Submission program with the FDA for its Helix Transendocardial Delivery Catheter, a key step towards regulatory approval.
  • Successful completion of the Pre-Submission process could indicate progress in BioCardia's efforts to commercialize its catheter technology for intramyocardial therapeutic and diagnostic agent delivery.
  • Investors may want to monitor further updates on the FDA review process and the potential timeline for the Helix Catheter's approval and commercialization.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-02-04

Key Insights

  • Peter Altman, the President and CEO of BioCardia, Inc. (BCDA), has acquired 5,000 shares of the company's common stock at $1.13 per share, increasing his direct beneficial ownership to 273,866 shares.
  • This insider buying activity suggests that Altman has confidence in the company's future prospects and is willing to invest his own capital in the stock.
  • Insider buying can be a positive signal for investors, as it may indicate that management believes the stock is undervalued and has growth potential.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-01-21

Key Insights

  • Insider Peter Altman, the President and CEO of BioCardia, Inc., has acquired 600 shares of common stock at $1.32 per share and an additional 300 shares at $1.34 per share, indicating his confidence in the company's prospects.
  • The transactions occurred within a short timeframe, suggesting Altman's belief that the stock is currently undervalued and presents a favorable investment opportunity.
  • Insider ownership is an important signal for investors, as it aligns the interests of management with those of shareholders and can indicate positive future prospects for the company.
Sentiment: Positive Significance: 7/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.